Yes, very few options traded, which I guess is unusual given the strong moves up and down we've had recently.
Darzalex sales were $1,986 for Q2 ($1,856M in Q1). According to JPM this was +146M (!) vs cons. Before the JNJ report JPM expected Halo royalty rev for 2022 to be $312M (cons 313M) above guidance of $300M. They see Darzalex Faspro reaching 90% penetration in US by the end the year. I suppose some analysts may revise their estimates and Helen may raise her $300M guidance a little.
News 
Market Data 
Discover 
